Literature DB >> 20186452

Prevalence of antibiotics resistance and OXA carbapenemases genes in multidrug-resistant Acinetobacter baumannii isolates in central Taiwan.

S-C Yang1, W-J Chang, Y-H Chang, Y-S Tsai, T-P Yang, C-W Juan, M-Y Shiau.   

Abstract

This study analyzed the prevalence of antibiotics resistance and the distribution of genes responsible for carbapenems resistance in Acinetobacter baumannii isolates. Clinical A. baumannii isolates were cultured, identified, and collected during the period from May 2007 to February 2009. Antibiotics resistance rates of the clinical isolates were analyzed by antimicrobial susceptibility testing. The distribution of carbapenemase alleles were investigated in the multidrug-resistant (MDR) A. baumannii isolates by multiplex polymerase chain reaction (PCR) techniques. A total of 1,265 independent A. baumannii isolates were identified. Approximately 70% of the clinical isolates were resistant to ampicillin/sulbactam, followed by imipenem, meropenem, cefepime, piperacillin/tazobactam, ceftazidime, and cefoperazone. Overall, 15.18% (192/1,265) of the isolates were characterized as MDR strains. All of the MDR A. baumannii isolates carried the bla (OXA51-like) allele. The detection rate of the bla (OXA23-like) and bla (OXA24-like) alleles was 96.35% (185/192) and 0.52% (1/192), respectively. Most of the isolates (185/192, 96.35%) carried genes which encode more than one carbapenemase. This report demonstrated that approximately 15% of A. baumannii clinical isolates in central Taiwan are MDR strains, with most of them harboring multiple carbapenemases. This study provides updated data regarding the prevalence of beta-lactam resistance and genotyping information of carbapenems resistance of A. baumannii in central Taiwan.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20186452     DOI: 10.1007/s10096-010-0878-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

Review 1.  The epidemiology and control of Acinetobacter baumannii in health care facilities.

Authors:  Pierre Edouard Fournier; Hervé Richet
Journal:  Clin Infect Dis       Date:  2006-01-26       Impact factor: 9.079

Review 2.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

3.  Worldwide emergence of carbapenem-resistant Acinetobacter spp.

Authors:  M Afzal-Shah; D M Livermore
Journal:  J Antimicrob Chemother       Date:  1998-05       Impact factor: 5.790

Review 4.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.

Authors:  E Bergogne-Bérézin; K J Towner
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

5.  Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study.

Authors:  J L García-Garmendia; C Ortiz-Leyba; J Garnacho-Montero; F J Jiménez-Jiménez; C Pérez-Paredes; A E Barrero-Almodóvar; M Gili-Miner
Journal:  Clin Infect Dis       Date:  2001-08-22       Impact factor: 9.079

6.  Epidemiological significance of cutaneous, pharyngeal, and digestive tract colonization by multiresistant Acinetobacter baumannii in ICU patients.

Authors:  J Ayats; X Corbella; C Ardanuy; M A Domínguez; A Ricart; J Ariza; R Martin; J Liñares
Journal:  J Hosp Infect       Date:  1997-12       Impact factor: 3.926

7.  Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam.

Authors:  E S Go; C Urban; J Burns; B Kreiswirth; W Eisner; N Mariano; K Mosinka-Snipas; J J Rahal
Journal:  Lancet       Date:  1994-11-12       Impact factor: 79.321

Review 8.  Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.

Authors:  Rupali Jain; Larry H Danziger
Journal:  Ann Pharmacother       Date:  2004-07-27       Impact factor: 3.154

9.  The status of antimicrobial resistance in Taiwan among gram-negative pathogens: the Taiwan surveillance of antimicrobial resistance (TSAR) program, 2000.

Authors:  Tsai-Ling Lauderdale; L Clifford McDonald; Yih-Ru Shiau; Pei-Chen Chen; Hui-Ying Wang; Jui-Fen Lai; Monto Ho
Journal:  Diagn Microbiol Infect Dis       Date:  2004-03       Impact factor: 2.803

10.  Multidrug-resistant Acinetobacter baumannii.

Authors:  Aharon Abbo; Shiri Navon-Venezia; Orly Hammer-Muntz; Tami Krichali; Yardena Siegman-Igra; Yehuda Carmeli
Journal:  Emerg Infect Dis       Date:  2005-01       Impact factor: 6.883

View more
  4 in total

1.  Types and prevalence of carbapenem-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex in Northern Taiwan.

Authors:  Wen-Shyang Hsieh; Nai-Yu Wang; Jou-An Feng; Li-Chuan Weng; Hsueh-Hsia Wu
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

2.  Acinetobacter infections and outcomes at an academic medical center: a disease of long-term care.

Authors:  Jennifer Townsend; An Na Park; Rita Gander; Kathleen Orr; Doramarie Arocha; Song Zhang; David E Greenberg
Journal:  Open Forum Infect Dis       Date:  2015-03-12       Impact factor: 3.835

Review 3.  Update on the Epidemiology, Treatment, and Outcomes of Carbapenem-resistant Acinetobacter infections.

Authors:  Uh Jin Kim; Hee Kyung Kim; Joon Hwan An; Soo Kyung Cho; Kyung-Hwa Park; Hee-Chang Jang
Journal:  Chonnam Med J       Date:  2014-08-20

4.  Carbapenem-resistant Acinetobacter baumannii from Air and Patients of Intensive Care Units.

Authors:  Meijie Jiang; Yunqing Mu; Ning Li; Zhijun Zhang; Shulin Han
Journal:  Pol J Microbiol       Date:  2018
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.